Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
No surprise, Shkreli weighed in during the media frenzy with support for Mylan. Critics say Mylan has been emboldened by the recall of EpiPen’s only competition last fall. Alex Lash contributed to this report. Drug pricing rhetoric had dissipated over the past few months, leading to a steady biotech rally over the summer.
40 
Let's personalize your content